The flow chart of guiding clinical application of immune checkpoint blockade therapy for KRAS-mutant lung adenocarcinomas in combination with TP53 and LKB1.
CT, chemotherapy; IHC, immunohistochemistry; LUAD, lung adenocarcinoma; NGS, next-generation sequencing; PD-L1, programmed death-l.